PIRS News and Press, Pieris Pharmaceuticals Inc. From 05/02/19

Founded by a Nobel prize winner, Bicycle Therapeutics ( BCYC ) has developed a large amount of intangible assets, which should interest investors. Besides, the company reports collaboration agreements with larger pharmaceutical institutions, cash in hand, and no debt. While Bicycle is still at...

Quick Take Bicycle Therapeutics ( BCYC ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing antibody-like therapeutics for the treatment of underserved diseases. BCYC has developed several commercial c...

BOSTON, MA / ACCESSWIRE / April 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan R...

BOSTON, MA / ACCESSWIRE / April 2, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today announ...

Pieris Pharmaceuticals, Inc. (PIRS) Q4 2018 Results Earnings Conference Call March 12, 2019, 08:00 AM ET Company Participants Allan Reine - Senior VP, CFO & Treasurer Stephen Yoder - CEO, President Louis Matis - Senior VP & Chief Development Officer Conference Call Par...

Company to Host an Investor Conference Call on Tuesday, March 12, 2019 at 8:00 am EDT BOSTON, MA / ACCESSWIRE / March 12, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Antical...

BOSTON, MA / ACCESSWIRE / March 6, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory, cancer and other diseases, announced today that S...

BOSTON, MA / ACCESSWIRE / March 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory, cancer and other diseases, announced today that it will host a fu...

On February 6, 2019, MacroGenics ( MGNX ) reported that the SOPHIA trial comparing margetuximab plus chemotherapy to Herceptin plus chemotherapy met the primary endpoint of progression free survival with a hazard ratio of 0.76 with an accompanying p-value of 0.033. This rather surprising res...

The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti...